Brief Overview on "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture"

The COVID-19 pandemic remains a pressing global challenge. Worldwide mortality attributable to COVID-19 now exceeds 4 million deaths. There is an urgent need for developing novel therapeutics to treat SARS-CoV-2. Our recent study showed brilacidin, a synthetic small molecule with peptide-like properties, potently inhibits SARS-CoV-2 in cell culture. Additionally, brilacidin exhibited in vitro inhibition in combination with remdesivir, the only FDA-approved drug for treatment of COVID-19. Brilacidin is currently undergoing Phase 2 clinical testing for treatment of moderate-to-severe COVID-19 in hospitalized patients.

Author(s):

Warren K. Weston*,Jane A. Harness and Aarthi Narayanan

Abstract | Full-Text | PDF

Share this